Sample sizes for designing bioequivalence studies for highly variable drugs

Journal of Pharmacy and Pharmaceutical Sciences

Volumn 15, Issue 1, 2011, Pages 73-84

  Tothfalusi, Laszlo ^a   Endrenyi, Laszlo ^b  

^a SEMMELWEIS UNIVERSITY   (Hungary)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BIOEQUIVALENCE; COMPUTER PROGRAM; COMPUTER SIMULATION; CONTROLLED STUDY; EUROPEAN MEDICINE AGENCY; FOOD AND DRUG ADMINISTRATION; GEOMETRIC MEAN RATIO; HEALTH CARE ORGANIZATION; MATHEMATICAL COMPUTING; MATHEMATICS; OBSERVER VARIATION; SAMPLE SIZE; STATISTICAL ANALYSIS;

HUMANS; SAMPLE SIZE; THERAPEUTIC EQUIVALENCY; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84856186304     PISSN: None     EISSN: 14821826     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. L. Tothfalusi, L. Endrenyi, and A. Garcia Areta. Evaluation of bioequivalence for highly variable drugs with scaled average bioequivalence. Clin. Pharmacokin. 48: 725-743 (2009).
2. European Medicines Agency. Guideline on the investigation of bioequivalence. London, United Kingdom, January 20, 2010. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2010/01/WC500070039.p df.
3. S.H. Haidar, B. Davit, M.-L. Chen, D. Conner, L. M. Lee, Q. H. Li, R. Lionberger, F. Makhlouf, D. Patel, D.J. Schuirmann, and L.X. Yu. Bioequivalence approaches for highly variable drugs and drug products. Pharm. Res.15: 237-241 (2008).
4. L. Tothfalusi, L. Endrenyi, K.K. Midha, M.J. Rawson, and J.W. Hubbard. Evaluation of the bioequivalence of highly-variable drugs and drug products. Pharm. Res. 18: 728-733 (2001).
5. K. F. Phillips. Power of the two one-sided tests procedure in bioequivalence. J. Pharmacokin. Biopharm. 18: 137-144 (1990).
6. E. Diletti E, D. Hauschke, and V. W. Steinijans. Sample size determination for bioequivalence assessment by means of confidence intervals. Int. J. Pharm. Ther. Toxicol. 29: 1-8 (1991).
7. D. Hauschke, V. W. Steinijans, E. Diletti, and M. Burke. Sample size determination for bioequivalence assessment using a multiplicative model. J. Pharmacokin. Biopharm. 20: 557-561 (1992).
8. J. P. Liu and S. C. Chow. Sample size determination for the two one-sided test procedure in bioequivalence. J. Pharmacokin. Biopharm. 20: 101-104 (1992).
9. D. Hauschke, V. Steinijans, and I. Pigeot. Bioequivalence Studies in Drug Development: Methods and Applications. Chichester: Wiley; 2007.
10. D. Schuirmann. A comparison of the two one-sided tests procedure and the power approach assessing the equivalence of average bioavailability. J. Pharmacokin. Biopharm. 15: 657-680 (1987).
11. A.W. Boddy, F.C. Snikeris, R.O. Kringle, G.C.G. Wei, J.A. Opperman, and K.K. Midha. An approach for widening the bioequivalence acceptance limits in the case of highly variable drugs. Pharm. Res. 12: 1865-1868 (1995).
12. L. Tothfalusi, and L. Endrenyi. Limits for the scaled average bioequivalence of highly variable drugs and drug products. Pharm. Res. 20: 382-389 (2003).
13. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM209294.pdf
14. V. W. Steinijans and D. Hauschke. Update on the statistical analysis of bioequivalence studies. Int. J. Clin. Pharmacol. Ther. Toxicol. 28: 105-110 (1990).
15. S.H. Haidar, F. Makhlouf, D.J. Schuirmann, T. Hyslop, B. Davit, D. Conner, and L.X. Yu. Evaluation of a scaling approach for the bioequivalence of highly variable drugs. AAPS J. 10: 450-454 (2008).
16. L. Endrenyi and L. Tothfalusi. Regulatory conditions for the determination of bioequivalence of highly variable drugs. J. Pharm. Pharmaceut. Sci. 12: 138-149 (2009).